Apolipoprotein B - An ideal biomarker for atherosclerosis?

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Biomarker Discovery

Background:

• Atherosclerosis is a leading cause of cardiovascular disease.
• Dyslipidemia management often involves complex lipid profiles.
• Apolipoprotein B (Apo-B) is a component of atherogenic lipoproteins.

Purpose of the Study:

• To review the pathophysiological role of Apo-B in atherosclerosis.
• To summarize evidence supporting Apo-B as a cardiovascular risk predictor.
• To examine current guidelines on Apo-B in dyslipidemia management.

Main Methods:

• Literature review of pathophysiological mechanisms.
• Synthesis of evidence on Apo-B as a predictive biomarker.
• Analysis of international treatment guidelines for dyslipidemia.

Main Results:

• Apo-B is present in all atherogenic lipoprotein particles (VLDL, IDL, LDL, Lp(a)).
• Plasma Apo-B concentration directly reflects the number of atherogenic particles.
• Apo-B integrates information from triglycerides and cholesterol, serving as a singular atherogenic lipid marker.

Conclusions:

• Apo-B is a valuable biomarker for atherosclerosis.
• Measuring Apo-B can simplify and enhance atherosclerotic cardiovascular disease care.
• Further integration of Apo-B into clinical practice is recommended for dyslipidemia management.